Ran An, Xiaolei Wang, Ligui Xiong, Yanqi Yang, Peiling Li
{"title":"TNF-α抑制剂治疗黄芪多糖诱导的高危妊娠的病例系列。","authors":"Ran An, Xiaolei Wang, Ligui Xiong, Yanqi Yang, Peiling Li","doi":"10.1017/cts.2025.10097","DOIUrl":null,"url":null,"abstract":"<p><p>We deliberated a case report of seven cases to investigate whether inhibitors of tumor necrosis factor-α (TNF-) could reduce pregnancy dangers caused by antiphospholipid syndrome (APS). Patient 1 was diagnosed with NC-OAPS and Hashimoto, Patient 3 was with SN-APS and Hashimoto, Patient 2, 3, 4 were with SN-APS, Patient 5 and 6 were with OAPS, and Patient 7 was with OAPS and PCOS. Patient 4 took the longest period to report the disappearance of symptoms (7 days), followed by patients 1 and 5, and lastly, 2, 3, 6 and 7; after treatment, TNF-α decreased to varying degrees in 7 patients, among which Patient 1, 3, 6, 7 reached the ideal level (< 8.1) and Patient 5 reached the highest level (123.04); Patient 6 and 7 were ongoing pregnancies. The fetuses were born to the desired gestational age except the fetus from Patient 1. A total of 5 patients underwent cesarean delivery. The average height of the newborns was 48.20 cm and the average weight was 2.50 kg. The Apgar scores ranged between 8 and 10. The ongoing pregnancies as a limitation of the dataset. Collectively, we found that TNF-α Inhibitors could prolong gestational period.</p>","PeriodicalId":15529,"journal":{"name":"Journal of Clinical and Translational Science","volume":"9 1","pages":"e186"},"PeriodicalIF":2.0000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444713/pdf/","citationCount":"0","resultStr":"{\"title\":\"A case series on TNF-α inhibitors for APS- induced high-risk pregnancies.\",\"authors\":\"Ran An, Xiaolei Wang, Ligui Xiong, Yanqi Yang, Peiling Li\",\"doi\":\"10.1017/cts.2025.10097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We deliberated a case report of seven cases to investigate whether inhibitors of tumor necrosis factor-α (TNF-) could reduce pregnancy dangers caused by antiphospholipid syndrome (APS). Patient 1 was diagnosed with NC-OAPS and Hashimoto, Patient 3 was with SN-APS and Hashimoto, Patient 2, 3, 4 were with SN-APS, Patient 5 and 6 were with OAPS, and Patient 7 was with OAPS and PCOS. Patient 4 took the longest period to report the disappearance of symptoms (7 days), followed by patients 1 and 5, and lastly, 2, 3, 6 and 7; after treatment, TNF-α decreased to varying degrees in 7 patients, among which Patient 1, 3, 6, 7 reached the ideal level (< 8.1) and Patient 5 reached the highest level (123.04); Patient 6 and 7 were ongoing pregnancies. The fetuses were born to the desired gestational age except the fetus from Patient 1. A total of 5 patients underwent cesarean delivery. The average height of the newborns was 48.20 cm and the average weight was 2.50 kg. The Apgar scores ranged between 8 and 10. The ongoing pregnancies as a limitation of the dataset. Collectively, we found that TNF-α Inhibitors could prolong gestational period.</p>\",\"PeriodicalId\":15529,\"journal\":{\"name\":\"Journal of Clinical and Translational Science\",\"volume\":\"9 1\",\"pages\":\"e186\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444713/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical and Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/cts.2025.10097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/cts.2025.10097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
A case series on TNF-α inhibitors for APS- induced high-risk pregnancies.
We deliberated a case report of seven cases to investigate whether inhibitors of tumor necrosis factor-α (TNF-) could reduce pregnancy dangers caused by antiphospholipid syndrome (APS). Patient 1 was diagnosed with NC-OAPS and Hashimoto, Patient 3 was with SN-APS and Hashimoto, Patient 2, 3, 4 were with SN-APS, Patient 5 and 6 were with OAPS, and Patient 7 was with OAPS and PCOS. Patient 4 took the longest period to report the disappearance of symptoms (7 days), followed by patients 1 and 5, and lastly, 2, 3, 6 and 7; after treatment, TNF-α decreased to varying degrees in 7 patients, among which Patient 1, 3, 6, 7 reached the ideal level (< 8.1) and Patient 5 reached the highest level (123.04); Patient 6 and 7 were ongoing pregnancies. The fetuses were born to the desired gestational age except the fetus from Patient 1. A total of 5 patients underwent cesarean delivery. The average height of the newborns was 48.20 cm and the average weight was 2.50 kg. The Apgar scores ranged between 8 and 10. The ongoing pregnancies as a limitation of the dataset. Collectively, we found that TNF-α Inhibitors could prolong gestational period.